Glial fibrillary acidic protein mutations in infantile, juvenile, and adult forms of Alexander disease

Annals of Neurology

Volumn 57, Issue 3, 2005, Pages 310-326

  Li, Rong ^a   Johnson, Anne B ^b   Salomons, Gajja ^c   Goldman, James E ^d   Naidu, Sakkubai ^e   Quinlan, Roy ^f   Cree, Bruce ^g   Ruyle, Stephanie Z ^h   Banwell, Brenda ⁱ   D'Hooghe, Marc ^j   Siebert, Joseph R ^k,l   Rolf, Cristin M ^m,n   Cox, Helen ^o   Reddy, Alyssa ^p   Gutiérrez Solana, Luis González ^q   Collins, Amanda ^r   Weller, Roy O ^s   Messing, Albee ^t   Van Der Knaap, Marjo S ^c   Brenner, Michael ^a  

^a University of Alabama at Birmingham   (United States)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^d Och Spine at New York Presbyterian Hospitals   (United States)

^e JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f DURHAM UNIVERSITY   (United Kingdom)

^g UCSF Multiple Sclerosis Center   (United States)

^h CHILDREN S HOSPITAL   (United States)

ⁱ HOSPITAL FOR SICK CHILDREN   (Canada)

^j Hospital Sint Jan   (Belgium)

^k SEATTLE CHILDREN S RESEARCH INSTITUTE   (United States)

^l UNIVERSITY OF WASHINGTON   (United States)

^m Cuyahoga County Coroner's Office   (United States)

ⁿ UNIVERSITY OF KENTUCKY   (United States)

^o BIRMINGHAM WOMEN S HOSPITAL   (United Kingdom)

^p UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^q HOSPITAL INFANTIL UNIVERSITARIO NIÑO JESÚS   (Spain)

^r Wessex Clinical Genetics Service   (United Kingdom)

^s UNIVERSITY OF SOUTHAMPTON   (United Kingdom)

^t UNIVERSITY OF WISCONSIN MADISON   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; GENOMIC DNA; GLIAL FIBRILLARY ACIDIC PROTEIN; MUTANT PROTEIN;

ADULT; ALEXANDER DISEASE; ARTICLE; ASTROCYTE; ATAXIA; CHILD; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENOTYPE PHENOTYPE CORRELATION; HUMAN; INFANT; MACROCEPHALY; MALE; NEUROLOGIC DISEASE; NEUROPATHOLOGY; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEOTIDE SEQUENCE; ONSET AGE; PRIORITY JOURNAL; PROGNOSIS; SEIZURE; SPASTICITY;

ADOLESCENT; ADRENOCORTICAL CARCINOMA; ADULT; AGE FACTORS; AGE OF ONSET; ALEXANDER DISEASE; CELL LINE, TUMOR; CHILD; CHILD, PRESCHOOL; DNA MUTATIONAL ANALYSIS; FEMALE; GLIAL FIBRILLARY ACIDIC PROTEIN; HUMANS; INFANT; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MODELS, MOLECULAR; MUTAGENESIS; MUTATION, MISSENSE; TRANSFECTION;

EID: 20044372525     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/ana.20406     Document Type: Article

References (92)

1. Russo LS Jr, Aron A, Anderson PJ. Alexander's disease: a report and reappraisal. Neurology 1976;26:607-614.
2. Messing A, Goldman JE, Johnson AB, Brenner M. Alexander disease: new insights from genetics. J Neuropathol Exp Neurol 2001;60:263-273.
3. Johnson AB, Brenner M. Alexander disease: clinical, pathological and genetic features. J Child Neurol 2003;18:625-632.
4. Messing A, Goldman JE. Alexander disease. In: Lazzarini RA, ed. Myelin and its diseases. San Diego: Academic Press, 2004: 851-866.
5. Rosenthal W. Über eine eigenthümliche, mit Syringomyelie komplizierte Geschwulst des Rückenmarks. (Bietr) Betrieb Pathol Anat 1898;23:111-143.
6. Alexander WS. Progressive fibrinoid degeneration of fibrillary astrocytes associated with mental retardation in a hydrocephalic infant. Brain 1949;72:373-381.
7. Johnson AB, Bettica A. On-grid immunogold labeling of glial intermediate filaments in epoxy-embedded tissue. Am J Anat 1989;185:335-341.
8. Tomokane N, Iwaki T, Tateisha J, et al. Rosenthal fibers share epitopes with αB-crystallin, glial fibrillary acidic protein, and ubiquitin, but not with vimentin. Immunoelectron microscopy with colloidal gold. Am J Pathol 1991;138:875-885.
9. Iwaki T, Kume-Iwaki A, Liem RK, Goldman JE. Alpha B-crystallin is expressed in non-lenticular tissues and accumulates in Alexander's disease brain. Cell 1989;57:71-78.
10. Iwaki T, Iwaki A, Tateishi J, et al. Alpha B-crystallin and 27-kd heat shock protein are regulated by stress conditions in the central nervous system and accumulate in Rosenthal fibers. Am J Pathol 1993;143:487-495.
11. Grcevic N, Yates PO. Rosenthal fibers in tumors of the central nervous system. J Pathol Bacteriol 1957;73:467-472.
12. Schlote W. [Piloid astrocytes (spongiocytes) and Rosenthal fibers in multiple sclerosis (author's transl)]. Acta Neuropathol (Berl) 1975;33:35-44.
13. Brenner M, Johnson AB, Boespflug-Tanguy O, et al. Mutations in GFAP, encoding glial fibrillary acidic protein, are associated with Alexander disease. Nat Genet 2001;27:117-120.
14. Strelkov SV, Herrmann H, Aebi U. Molecular architecture of intermediate filaments. Bioessays 2003;25:243-251.
15. Gingold MK, Bodensteiner JB, Schochet SS, Jaynes M. Alexander's disease: unique presentation. J Child Neurol 1999;14: 325-329.
16. Bassuk AG, Joshi A, Burton BK, et al. Alexander disease with serial MRS and a new mutation in the glial fibrillary acidic protein gene. Neurology 2003;61:1014-1015.
17. Deprez M, D'Hooghe M, Misson JP, et al. Infantile and juvenile presentations of Alexander's disease: a report of two cases. Acta Neurol Scand 1999;99:158-165. (Erratum in: Acta Neurol Scand 1999;100:354.)
18. Deprez M, D'Hooghe M, Misson JP, et al. Infantile and juvenile presentations of Alexander's disease: a report of two cases. Acta Neurol Scand 1999;99:158-165. (Erratum in: Acta Neurol Scand 1999;100:354.)
19. Coombs NJ, Gough AC, Primrose JN. Optimisation of DNA and RNA extraction from archival formalin-fixed tissue. Nucleic Acids Res 1999;27:e12.
20. Ip YT, Jackson V, Meier J, Chalkley R. The separation of transcriptionally engaged genes. J Biol Chem 1988;263: 14044-14052.
21. Solomon MJ, Varshavsky A. Formaldehyde-mediated DNA-protein crosslinking: a probe for in vivo chromatin structures. Proc Natl Acad Sci U S A 1985;82:6470-6474.
22. Li R, Messing A, Goldman JE, Brenner M. GFAP mutations in Alexander disease. Int J Dev Neurosci 2002;20:259-268.
23. Brenner M, Lampel K, Nakatani Y, et al. Characterization of human cDNA and genomic clones for glial fibrillary acidic protein. Brain Res Mol Brain Res 1990;7:277-286.
24. Sekimata M, Tsujimura K, Tanaka J, et al. Detection of protein kinase activity specifically activated at metaphase-anaphase transition. J Cell Biol 1996;132:635-641.
25. Hedberg KK, Chen LB. Absence of intermediate filaments in a human adrenal cortex carcinoma-derived cell line. Exp Cell Res 1986;163:509-517.
26. Van der Knaap MS, Naidu S, Breiter SN, et al. Alexander disease: diagnosis with MR imaging. Am J Neuroradiol 2001; 22:541-552.
27. Van der Knaap MS, Salomons GS, Li R, et al. Unusual variants of Alexander disease. Ann Neurol 2005;00:00-00.
28. Nachman MW, Crowell SL. Estimate of the mutation rate per nucleotide in humans. Genetics 2000;156:297-304.
29. den Dunnen JT, Antonarakis SE. Nomenclature for the description of human sequence variations. Hum Genet 2001;109: 121-124.
30. Bongcam-Rudloff E, Nister M, Betsholtz C, et al. Human glial fibrillary acidic protein: complementary DNA cloning, chromosome localization, and messenger RNA expression in human glioma cell lines of various phenotypes. Cancer Res 1991;51: 1553-1560.
31. Gorospe JR, Naidu S, Johnson AB, et al. Molecular findings in symptomatic and pre-symptomatic Alexander disease patients. Neurology 2002;58:1494-1500.
32. Rodriguez D, Gauthier F, Bertini E, et al. Infantile Alexander disease: spectrum of GFAP mutations and genotype-phenotype correlation. Am J Hum Genet 2001;69:1134-1140.
33. Shiroma N, Kanazawa N, Kato Z, et al. Molecular genetic study in Japanese patients with Alexander disease: a novel mutation, R79L. Brain Dev 2003;25:116-121.
34. Meins M, Brockmann K, Yadav S, et al. Infantile Alexander disease: a GFAP mutation in monozygotic twins and novel mutations in two other patients. Neuropediatrics 2002;33: 194-198.
35. Shiroma N, Kanazawa N, Izumi M, et al. Diagnosis of Alexander disease in a Japanese patient by molecular genetic analysis. J Hum Genet 2001;46:579-582.
36. Trollmann R, Kraus C, Orlova N, et al. In vivo diagnosis of infantile Alexander disease by molecular genetic analysis of GFAP gene [German]. Monatsschrift für Kinderheilkunde 2003;151:311-314.
37. Imamura A, Orii KE, Mizuno S, et al. MR imaging and 1H-MR spectroscopy in a case of juvenile Alexander disease. Brain Dev 2002;24:723-726.
38. Probst EN, Hagel C, Weisz V, et al. Atypical focal MRI lesions in a case of juvenile Alexander's disease. Ann Neurol 2003;53: 118-120.
39. Shiihara T, Kato M, Honma T, et al. Fluctuation of computed tomographic findings in white matter in Alexander's disease. J Child Neurol 2002;17:227-230.
40. Aoki Y, Haginoya K, Munakata M, et al. A novel mutation in glial fibrillary acidic protein gene in a patient with Alexander disease. Neurosci Lett 2001;312:71-74.
41. Sawaishi Y, Yano T, Takaku I, Takada G. Juvenile Alexander disease with a novel mutation in glial fibrillary acidic protein gene. Neurology 2002;58:1541-1543.
42. Stumpf E, Massen H, Duquette A, et al. Adult Alexander disease with autosomal dominant transmission: a distinct entity caused by mutation in the glial fibrillary acid protein gene. Arch Neurol 2003;60:1307-1312.
43. Okamoto Y, Mitsuyama H, Jonosono M, et al. Autosomal dominant palatal myoclonus and spinal cord atrophy. J Neurol Sci 2002;195:71-76.
44. Brockmann K, Meins M, Taubert A, et al. A novel GFAP mutation and disseminated white matter lesions: adult Alexander disease? Eur Neurol 2003;50:100-105.
45. Namekawa M, Takiyama Y, Aoki Y, et al. Identification of GFAP gene mutation in hereditary adult-onset Alexander's disease. Ann Neurol 2002;52:779-785.
46. Kinoshita T, Imaizumi T, Miura Y, et al. A case of adult-onset Alexander disease with Arg416Trp human glial fibrillary acidic protein gene mutation. Neurosci Lett 2003;350:169-172.
47. Thyagarajan D, Chataway T, Li R, et al. Dominantly-inherited adult-onset leukodystrophy with palatal tremor caused by a mutation in the glial fibrillary acidic protein gene. Mov Disord 2004;19:1244-1248.
48. Hennies HC, Zehender D, Kunze J, et al. Keratin 9 gene mutational heterogeneity in patients with epidermolytic palmoplantar keratoderma. Hum Genet 1994;93:649-654.
49. Covello SP, Irvine AD, McKenna KE, et al. Mutations in keratin K9 in kindreds with epidermolytic palmoplantar keratoderma and epidemiology in Northern Ireland. J Invest Dermatol 1998;111:1207-1209.
50. Syder AJ, Yu QC, Paller AS, et al. Genetic mutations in the K1 and K10 genes of patients with epidermolytic hyperkeratosis. Correlation between location and disease severity. J Clin Invest 1994;93:1533-1542.
51. Paller AS, Syder AJ, Chan YM, et al. Genetic and clinical mosaicism in a type of epidermal nevus. N Engl J Med 1994;331: 1408-1415.
52. Corden LD, Swensson O, Swensson B, et al. Molecular genetics of Meesmann's corneal dystrophy: ancestral and novel mutations in keratin 12 (K12) and complete sequence of the human KRT12 gene. Exp Eye Res 2000;70:41-49.
53. Rugg E, Magee G, Wilson N, et al. Identification of two novel mutations in keratin 13 as the cause of white sponge naevus. Oral Dis 1999;5:321-324.
54. Cummins RE, Klingberg S, Wesley J, et al. Keratin 14 point mutations at codon 119 of helix 1A resulting in different epidermolysis bullosa simplex phenotypes. J Invest Dermatol 2001;117:1103-1107.
55. Chen H, Bonifas JM, Matsumura K, et al. Keratin 14 gene mutations in patients with epidermolysis bullosa simplex. J Invest Dermatol 1995;105:629-632.
56. Celebi JT, Tanzi EL, Yao YJ, et al. Mutation report: identification of a germline mutation in keratin 17 in a family with pachyonychia congenita type 2. J Invest Dermatol 1999;113: 848-850.
57. Nomura K, Shimizu H, Meng X, et al. A novel keratin K5 gene mutation in Dowling-Meara epidermolysis bullosa simplex. J Invest Dermatol 1996;107:253-254.
58. Endo H, Hatamochi A, Shinkai H. A novel mutation of a leucine residue in coil 1A of keratin 9 in epidermolytic palmoplantar keratoderma. J Invest Dermatol 1997;109: 113-115.
59. Ishiko A, Akiyama M, Takizawa Y, et al. A novel leucine to valine mutation in residue 7 of the helix initiation motif of keratin 10 leads to bullous congenital ichthyosiform erythroderma. J Invest Dermatol 2001;116:991-992.
60. Yamanishi K, Matsuki M, Konishi K, Yasuno H. A novel mutation of Leu122 to Phe at a highly conserved hydrophobic residue in the helix initiation motif of keratin 14 in epidermolysis bullosa simplex. Hum Mol Genet 1994;3:1171-1172.
61. Smith FJ, Fisher MP, Healy E, et al. Novel keratin 16 mutations and protein expression studies in pachyonychia congenita type 1 and focal palmoplantar keratoderma. Exp Dermatol 2000;9:170-177.
62. Yang JM, Chipev CC, DiGiovanna JJ, et al. Mutations in the H1 and 1A domains in the keratin 1 gene in epidermolytic hyperkeratosis. J Invest Dermatol 1994;102:17-23.
63. Arin MJ, Longley MA, Kuster W, et al. An asparagine to threonine substitution in the 1 domain of keratin 1: a novel mutation that causes epidermolytic hyperkeratosis. Exp Dermatol 1999;8:124-127.
64. Smith FJ, Maingi C, Covello SP, et al. Genomic organization and fine mapping of the keratin 2e gene (KRT2E): K2e V1 domain polymorphism and novel mutations in ichthyosis bullosa of Siemens. J Invest Dermatol 1998;111:817-821.
65. Takizawa Y, Akiyama M, Nagashima M, Shimizu H. A novel asparagine-aspartic acid mutation in the rod 1A domain in keratin 2e in a Japanese family with ichthyosis bullosa of Siemens. J Invest Dermatol 2000;14:193-195.
66. Whittock NV, Ashton GH, Griffiths WA, et al. New mutations in keratin 1 that cause bullous congenital ichthyosiform erythroderma and keratin 2e that cause ichthyosis bullosa of Siemens. Br Dermatol 2001;145:330-335.
67. Sorensen CB, Ladekjaer-Mikkelsen AS, Andresen BS, et al. Identification of novel and known mutations in the genes for keratin 5 and 14 in Danish patients with epidermolysis bullosa simplex: correlation between genotype and phenotype. J Invest Dermatol 1999;112:184-190.
68. Smith FJ, McKenna KE, Irvine AD, et al. A mutation detection strategy for the human keratin 6A gene and novel missense mutations in two cases of pachyonychia congenita type 1. Exp Dermatol 1999;8:109-114.
69. Korge BP, Hamm H, Jury CS, et al. Identification of novel mutations in basic hair keratins hHb1 and hHb6 in monilethrix: implications for protein structure and clinical phenotype. J Invest Dermatol 1999;113:607-612.
70. Torchard D, Blanchet-Bardon C, Serova O, et al. Epidermolytic palmoplantar keratoderma cosegregates with a keratin 9 mutation in a pedigree with breast and ovarian cancer. Nat Genet 1994;6:106-110.
71. Reis A, Hennies HC, Langbein L, et al. Keratin 9 gene mutations in epidermolytic palmoplantar keratoderma (EPPK). Nat Genet 1994;6:174-179.
72. Bonifas JM, Matsumura K, Chen MA, et al. Mutations of keratin 9 in two families with palmoplantar epidermolytic hyperkeratosis. J Invest Dermatol 1994;103:474-477.
73. Chipev CC, Yang JM, DiGiovanna JJ, et al. Preferential sites in keratin 10 that are mutated in epidermolytic hyperkeratosis. Am J Hum Genet 1994;54:179-190.
74. Terrinoni A, Rugg EL, Lane EB, et al. A novel mutation in the keratin 13 gene causing oral white sponge nevus. J Dent Res 2001;80:919-923.
75. Shamsher MK, Navsaria HA, Stevens HP, et al. Novel mutations in keratin 16 gene underly focal non-epidermolytic palmoplantar keratoderma (NEPPK) in two families. Hum Mol Genet 1995;4:1875-1881.
76. McLean WH, Rugg EL, Lunny DP, et al. Keratin 16 and keratin 17 mutations cause pachyonychia congenita. Nat Genet 1995;9:273-278.
77. Smith FJ, Corden LD, Rugg EL, et al. Missense mutations in keratin 17 cause either pachyonychia congenita type 2 or a phenotype resembling steatocystoma multiplex. J Invest Dermatol 1997;108:220-223.
78. Schuilenga-Hut PH, Vlies P, Jonkman MF, et al. Mutation analysis of the entire keratin 5 and 14 genes in patients with epidermolysis bullosa simplex and identification of novel mutations. Hum Mutat 2003;21:447.
79. Dong W, Ryynanen M, Uitto J. Identification of a leucine-to-proline mutation in the keratin 5 gene in a family with the generalized Kobner type of epidermolysis bullosa simplex. Hum Mutat 1993;2:94-102.
80. Chao SC, Yang MH, Lee SF. Novel KRT14 mutation in a Taiwanese patient with epidermolysis bullosa simplex (Kobner type). J Formos Med Assoc 2002;101:287-290.
81. Nishida K, Honma Y, Dota A, et al. Isolation and chromosomal localization of a cornea-specific human keratin 12 gene and detection of four mutations in Meesmann corneal epithelial dystrophy. Am J Hum Genet 1997;61:1268-1275.
82. Hut PH, v d Vlies P, Jonkman MF, et al. Exempting homologous pseudogene sequences from polymerase chain reaction amplification allows genomic keratin 14 hotspot mutation analysis. J Invest Dermatol 2000;114:616-619.
83. Ciubotaru D, Bergman R, Baty D, et al. Epidermolysis bullosa simplex in Israel: clinical and genetic features. Arch Dermatol 2003;139:498-505. (Erratum in: Arch Dermatol. 2003;139: 1084.)
84. Ciubotaru D, Bergman R, Baty D, et al. Epidermolysis bullosa simplex in Israel: clinical and genetic features. Arch Dermatol 2003;139:498-505. (Erratum in: Arch Dermatol. 2003;139: 1084.)
85. Rothnagel JA, Dominey AM, Dempsey LD, et al. Mutations in the rod domains of keratins 1 and 10 in epidermolytic hyperkeratosis. Science 1992:257:1128-1130.
86. Jones DO, Watts C, Mills C, et al. A new keratin 2e mutation in ichthyosis bullosa of Siemens. J Invest Dermatol 1997;108: 354-356.
87. Cooper DN, Youssoufian H. The CpG dinucleotide and human genetic disease. Hum Genet 1988;78:151-155.
88. Rugg EL, McLean WH, Lane EB, et al. A functional "knockout" of human keratin 14. Genes Dev 1994;8:2563-2573.
89. Jonkman MF, Heeres K, Pas HH, et al. Effects of keratin 14 ablation on the clinical and cellular phenotype in a kindred with recessive epidermolysis bullosa simplex. J Invest Dermatol 1996;107:764-769.
90. Wu KC, Bryan JT, Morasso MI, et al. Coiled-coil trigger motifs in the 1B and 2B rod domain segments are required for the stability of keratin intermediate filaments. Mol Biol Cell 2000; 11:3539-3558.
91. Fuchs E. The cytoskeleton and disease: genetic disorders of intermediate filaments. Annu Rev Genet 1996;30: 197-231.
92. Steinert PM, Marekov LN, Parry DA. Molecular parameters of type IV alpha-internexin and type IV-type III alpha-internexin-vimentin copolymer intermediate filaments. J Biol Chem 1999; 274:1657-1666.